NCT05494398View on ClinicalTrials.gov

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label

PHASE2/PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 12, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2028

Conditions
Autism Spectrum Disorder
Interventions
DRUG

N-acetylcysteine

12 week administration of N-Acetylcysteine to target restricted repetitive behavior severity.

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Stanford University

OTHER